196 related articles for article (PubMed ID: 35070982)
1. Notch2 Increases the Resistance to Venetoclax-Induced Apoptosis in Chronic Lymphocytic Leukemia B Cells by Inducing Mcl-1.
Fiorcari S; Maffei R; Atene CG; Mesini N; Maccaferri M; Leonardi G; Martinelli S; Paolini A; Nasillo V; Debbia G; Potenza L; Luppi M; Marasca R
Front Oncol; 2021; 11():777587. PubMed ID: 35070982
[TBL] [Abstract][Full Text] [Related]
2. AMG-176, an Mcl-1 Antagonist, Shows Preclinical Efficacy in Chronic Lymphocytic Leukemia.
Yi X; Sarkar A; Kismali G; Aslan B; Ayres M; Iles LR; Keating MJ; Wierda WG; Long JP; Bertilaccio MTS; Gandhi V
Clin Cancer Res; 2020 Jul; 26(14):3856-3867. PubMed ID: 31937611
[TBL] [Abstract][Full Text] [Related]
3. Targeting Mcl-1 by AMG-176 During Ibrutinib and Venetoclax Therapy in Chronic Lymphocytic Leukemia.
Yi X; Jain N; Iles LR; Ayres ML; Wierda WG; Gandhi V
Front Oncol; 2022; 12():833714. PubMed ID: 35273915
[TBL] [Abstract][Full Text] [Related]
4. Venetoclax resistance induced by activated T cells can be counteracted by sphingosine kinase inhibitors in chronic lymphocytic leukemia.
Sarapura Martinez VJ; Buonincontro B; Cassarino C; Bernatowiez J; Colado A; Cordini G; Custidiano MDR; Mahuad C; Pavlovsky MA; Bezares RF; Favale NO; Vermeulen M; Borge M; Giordano M; Gamberale R
Front Oncol; 2023; 13():1143881. PubMed ID: 37020867
[TBL] [Abstract][Full Text] [Related]
5. BCR signaling inhibitors differ in their ability to overcome Mcl-1-mediated resistance of CLL B cells to ABT-199.
Bojarczuk K; Sasi BK; Gobessi S; Innocenti I; Pozzato G; Laurenti L; Efremov DG
Blood; 2016 Jun; 127(25):3192-201. PubMed ID: 27095788
[TBL] [Abstract][Full Text] [Related]
6. Notch signaling sustains the expression of Mcl-1 and the activity of eIF4E to promote cell survival in CLL.
De Falco F; Sabatini R; Del Papa B; Falzetti F; Di Ianni M; Sportoletti P; Baldoni S; Screpanti I; Marconi P; Rosati E
Oncotarget; 2015 Jun; 6(18):16559-72. PubMed ID: 26041884
[TBL] [Abstract][Full Text] [Related]
7. Aberrantly expressed Wnt5a in nurse-like cells drives resistance to Venetoclax in chronic lymphocytic leukemia.
Guo Y; Pei H; Lu B; Zhang D; Zhao Y; Wu F; Sun H; Huang J; Li P; Yi C; Zhu C; Pan Y; Wu S; Chen C; Xu X; Chen Y
Cell Death Discov; 2022 Feb; 8(1):82. PubMed ID: 35210425
[TBL] [Abstract][Full Text] [Related]
8. ABT-737 resistance in B-cells isolated from chronic lymphocytic leukemia patients and leukemia cell lines is overcome by the pleiotropic kinase inhibitor quercetin through Mcl-1 down-regulation.
Russo M; Spagnuolo C; Volpe S; Tedesco I; Bilotto S; Russo GL
Biochem Pharmacol; 2013 Apr; 85(7):927-36. PubMed ID: 23353698
[TBL] [Abstract][Full Text] [Related]
9. Potential mechanisms of resistance to venetoclax and strategies to circumvent it.
Tahir SK; Smith ML; Hessler P; Rapp LR; Idler KB; Park CH; Leverson JD; Lam LT
BMC Cancer; 2017 Jun; 17(1):399. PubMed ID: 28578655
[TBL] [Abstract][Full Text] [Related]
10. High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells.
Oppermann S; Ylanko J; Shi Y; Hariharan S; Oakes CC; Brauer PM; Zúñiga-Pflücker JC; Leber B; Spaner DE; Andrews DW
Blood; 2016 Aug; 128(7):934-47. PubMed ID: 27297795
[TBL] [Abstract][Full Text] [Related]
11. Venetoclax in the Treatment of Chronic Lymphocytic Leukemia: Evidence, Expectations, and Future Prospects.
Tariq S; Tariq S; Khan M; Azhar A; Baig M
Cureus; 2020 Jun; 12(6):e8908. PubMed ID: 32742874
[TBL] [Abstract][Full Text] [Related]
12. Tipping the Noxa/Mcl-1 balance overcomes ABT-737 resistance in chronic lymphocytic leukemia.
Tromp JM; Geest CR; Breij EC; Elias JA; van Laar J; Luijks DM; Kater AP; Beaumont T; van Oers MH; Eldering E
Clin Cancer Res; 2012 Jan; 18(2):487-98. PubMed ID: 22128299
[TBL] [Abstract][Full Text] [Related]
13. The first MCL-1-selective BH3 mimetics have therapeutic potential for chronic lymphocytic leukemia.
Besbes S; Pocard M; Mirshahi M; Billard C
Crit Rev Oncol Hematol; 2016 Apr; 100():32-6. PubMed ID: 26899021
[TBL] [Abstract][Full Text] [Related]
14. Targeting Nuclear NOTCH2 by Gliotoxin Recovers a Tumor-Suppressor NOTCH3 Activity in CLL.
Hubmann R; Schnabl S; Araghi M; Schmidl C; Rendeiro AF; Hilgarth M; Demirtas D; Ali F; Staber PB; Valent P; Zielinski C; Jäger U; Shehata M
Cells; 2020 Jun; 9(6):. PubMed ID: 32570839
[TBL] [Abstract][Full Text] [Related]
15. Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kδ or PKCβ signaling pathways.
Amigo-Jiménez I; Bailón E; Aguilera-Montilla N; Terol MJ; García-Marco JA; García-Pardo A
Oncotarget; 2015 Dec; 6(42):44832-48. PubMed ID: 26540567
[TBL] [Abstract][Full Text] [Related]
16. Interferon regulatory factor 4 attenuates Notch signaling to suppress the development of chronic lymphocytic leukemia.
Shukla V; Shukla A; Joshi SS; Lu R
Oncotarget; 2016 Jul; 7(27):41081-41094. PubMed ID: 27232759
[TBL] [Abstract][Full Text] [Related]
17. The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism.
Anderson MA; Deng J; Seymour JF; Tam C; Kim SY; Fein J; Yu L; Brown JR; Westerman D; Si EG; Majewski IJ; Segal D; Heitner Enschede SL; Huang DC; Davids MS; Letai A; Roberts AW
Blood; 2016 Jun; 127(25):3215-24. PubMed ID: 27069256
[TBL] [Abstract][Full Text] [Related]
18. Microenvironmental agonists generate
Jayappa KD; Portell CA; Gordon VL; Capaldo BJ; Bekiranov S; Axelrod MJ; Brett LK; Wulfkuhle JD; Gallagher RI; Petricoin EF; Bender TP; Williams ME; Weber MJ
Blood Adv; 2017 Jun; 1(14):933-946. PubMed ID: 29034364
[No Abstract] [Full Text] [Related]
19. Inhibition of cyclin-dependent kinase 9 synergistically enhances venetoclax activity in mantle cell lymphoma.
Zhao X; Bodo J; Chen R; Durkin L; Souers AJ; Phillips DC; Hsi ED
EJHaem; 2020 Jul; 1(1):161-169. PubMed ID: 35847704
[TBL] [Abstract][Full Text] [Related]
20. Pairing MCL-1 inhibition with venetoclax improves therapeutic efficiency of BH3-mimetics in AML.
Hormi M; Birsen R; Belhadj M; Huynh T; Cantero Aguilar L; Grignano E; Haddaoui L; Guillonneau F; Mayeux P; Hunault M; Tamburini J; Kosmider O; Fontenay M; Bouscary D; Chapuis N
Eur J Haematol; 2020 Nov; 105(5):588-596. PubMed ID: 32659848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
